CAPR — Capricor Therapeutics, Inc.

Summary of Capricor Therapeutics Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2026, Capricor reported approximately $279 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2027.
• Revenue: No revenue was recognized for Q1 2026 or Q1 2025.
• Operating Expenses: Total operating expenses for Q1 2026 were approximately $36.8 million, up from $25 million in Q1 2025, primarily due to investments in clinical, regulatory, and manufacturing activities.
• Net Loss: The net loss for Q1 2026 was approximately $33.9 million or $0.59 per share, compared to a net loss of $24.4 million or $0.53 per share in Q1 2025.

2. Strategic Updates and Business Highlights

• Regulatory Progress: The Biologics License Application (BLA) for deramiocel is under FDA review with a PDUFA target action date of August 22, 2026. The company is optimistic about the review process, having received and responded to numerous information requests from the FDA.
• Clinical Data: The HOPE-3 Phase 3 trial showed significant efficacy, including a 54% reduction in disease severity and a 91% slowing of disease progression in left ventricular ejection fraction for patients with cardiomyopathy.
• Legal Action: Capricor has initiated legal proceedings against NS Pharma and Nippon Shinyaku to rescind their distribution agreement, citing a flawed pricing structure that could hinder patient access to deramiocel.
• Commercial Readiness: The company is building its commercial team and manufacturing capacity, aiming for a launch of deramiocel independently if approved. They have secured a senior vice president of market access and are in the process of hiring a chief commercial officer.

3. Forward Guidance and Outlook

• Capricor expects to continue its path toward commercialization of deramiocel, focusing on patient access and building a robust infrastructure. The company aims to stockpile commercial doses once FDA labeling guidance is received and anticipates a strong launch post-approval.
• The company is also exploring expansion opportunities for deramiocel to younger DMD patients and other indications, including Becker Muscular Dystrophy.

4. Bad News, Challenges, or Points of Concern

• Legal Dispute: The ongoing lawsuit against NS Pharma raises uncertainties regarding distribution and commercialization strategies, which could delay patient access to deramiocel.
• Increased Expenses: Rising operating expenses may impact financial sustainability, especially with no current revenue.
• Regulatory Risks: While the BLA is under review, any unforeseen issues could affect the approval timeline and subsequent commercialization efforts.

5. Notable Q&A Insights

• Concerns Over NS Pharma: Management expressed disappointment with NS Pharma's lack of progress in launch planning post-CRL and indicated that the legal action was a last resort after unsuccessful negotiations.
• Commercial Strategy: Capricor is confident in its ability to build a commercial team and launch deramiocel independently, emphasizing the importance of relationships within the DMD community.
• Labeling Discussions: The company is in preliminary discussions with the FDA regarding labeling, which is crucial for manufacturing and distribution planning.
• Market Potential: The potential market for Becker Muscular Dystrophy was highlighted, with an estimated 5,000 patients in the U.S., indicating future growth opportunities.

Overall, Capricor is at a critical juncture with the potential approval of deramiocel, but faces challenges related to its partnership with NS Pharma and the need to establish a commercial presence independently.